Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.400
-0.400-1.55%
Volume:8.04M
Turnover:204.37M
Market Cap:22.15B
PE:27.55
High:26.650
Open:26.150
Low:24.900
Close:25.800
Loading ...

HUTCHMED Announces That It Has Completed Enrollment of a Phase Ii Registration Study of Fanregratinib (Hmpl-453) for Intrahepatic Cholangiocarcinoma in China

THOMSON REUTERS
·
1 hour ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

GlobeNewswire
·
Yesterday

Hutchmed Agrees to Dispose 35% of Subsidiary to GP Health Service Capital

MT Newswires Live
·
04 Mar

Maxland Malaysia 2nd-Quarter 2024 Earnings Summary Table

Dow Jones
·
28 Feb

Jiankun International Malaysia 2nd-Quarter 2024 Earnings Summary Table

Dow Jones
·
26 Feb

Lion Posim Malaysia 4th-Quarter 2024 Earnings Summary Table

Dow Jones
·
21 Feb

HUTCHMED to Announce 2024 Final Results

GlobeNewswire
·
19 Feb

BofA Securities Adjusts Price Target on HUTCHMED (China) to $27 From $26, Maintains Buy Rating

MT Newswires Live
·
11 Feb

Hutchmed Delays Circular Dispatch for Shanghai Hutchinson Pharma Stake Disposal

MT Newswires Live
·
29 Jan

BRIEF-Hutchmed (China) Says Disposal Of Stake In Shanghai Hutchison Pharmaceuticals

Reuters
·
28 Jan

HUTCHMED (China) - Expects Circular With Details on Terms of Disposal Will Be Dispatched on or Before Feb 28

THOMSON REUTERS
·
28 Jan

HUTCHMED (China) Ltd - Disposal of 45% Equity Interest in Shanghai Hutchison Pharmaceuticals Limited

THOMSON REUTERS
·
28 Jan

Hutchmed Gets China Approval for Non-Small Cell Lung Cancer Mutation

MT Newswires Live
·
14 Jan

Hutchmed Says Orpathys Receives Full Approval in China

MT Newswires Live
·
14 Jan

BRIEF-HUTCHMED (China) Says NMPA Granted Full Approval For Orpathys (Savolitinib) In China

Reuters
·
14 Jan

- HUTCHMED China Ltd - Full Approval for Orpathys in China

THOMSON REUTERS
·
14 Jan